I recently came across a review of “De novo molecular drug design benchmarking” by Lauren L. Grant and Clarissa S. Sit where they highlighted the recently proposed benchmarking methods including Fréchet ChemNet Distance [1], GuacaMol [2], and Molecular Sets (MOSES) [3] together with its current and future potential applications as well as the steps moving forward in terms of validation of benchmarking methods [4].

From this review, I particularly wanted to note about the issues with current benchmarking methods and the points we should be aware of when using these methods to benchmark our own de novo molecular design methods. Goal-directed models are referring to de novo molecular design methods optimizing for a particular scoring function [2].